Critical Path Institute

Critical Path Institute (C-Path) is a non-profit organization that optimizes drug and medical product development lifecycles by convening stakeholders across the pharmaceutical industry, government agencies, patient communities, and academic institutions.

C-Path operates disease-specific and cross-functional consortia that address critical gaps in drug development:

• Critical Path for Alzheimer's Disease — develops tools to optimize clinical trial designs, identify individuals best suited for trials, and define meaningful benefits for early-stage disease.
• Type 1 Diabetes (T1D) Consortium — translates scientific findings into actionable insights for decision-makers advancing therapeutic initiatives.
• Duchenne Regulatory Science Consortium (D-RSC) — focuses on regulatory science and accessibility for Duchenne muscular dystrophy development.
• ALS Research and Clinical Trial Design — addresses fragmented efforts by fostering collaboration among the FDA, NIH, C-Path, and patient advocates.
• CP-RND (Critical Path – Rare & Neglected Diseases) — a collaboration with the FDA and NIH to accelerate development through natural history data collection.

C-Path's mission is to make a difference for patients and their families by bridging communication gaps between scientists, regulators, industry, and patient communities, enabling more efficient and patient-centric drug development.